Hemostemix Inc. (CVE:HEM – Get Free Report) shares dropped 14.5% on Monday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 689,216 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The company has a market cap of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20. The company has a 50-day simple moving average of C$0.11 and a 200-day simple moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Short Selling: How to Short a Stock
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
- Trading Stocks: RSI and Why it’s Useful
- Teck Resources: America’s Ally in Rare Earth Elements
- P/E Ratio Calculation: How to Assess Stocks
- Best Buy’s Dividend Is a Bargain With Double-Digit Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
